Gadobutrol Injection Proposed for Selection in the 11th National Drug Centralized Procurement

2025/10/30

/uploads/image/2025/10/29/beilu-20251029.jpg

Recently, Beijing Beilu Pharmaceutical Co., Ltd. participated in the bidding work for the eleventh batch of national drug centralized procurement organized by Chinese National Organization for Drug Procurement, and the company's Gadobutrol Injection was selected.

References

Related News

Jiuwei Zhenxin Granules - Independent Innovation, Classic Inheritance
February 24, 2021A famous traditional prescription in Song Dynasty passed down for thousands of years.view
Introduction of Intravenous Contrast Media
December 27, 20211. The concept of intravenous contrast mediaThere are many types of contrast medium in the clinic, and different types of contrast medium will produce different feelings after they are injected into p...view
CPHI WORLDWIDE 2023
September 7, 2023DATE: 24 OCTOBER 2023 - 26 OCTOBER 2023VENUE: FIRA DE BARCELONA GRAN VIALOCATION: SPAIN. BARCELONAview
Foreign Journalists Visit Beilu Pharmaceutical to Learn about Beijing's Green Development
August 14, 2023On August 9, Beijing Foreign Affairs Office and Miyun District jointly organized 76 foreign journalists from 66 countries, including Brazil, Russia, Thailand and Saudi Arabia, to go into Miyun Distric...view
Beilu Pharmaceutical Obtains Drug Registration Certificate for Pramoxine Hydrochloride Sustained Release Tablets
July 7, 2023Recently, Beilu Pharmaceutical received the Drug Registration Certificate for two sizes (0.375mg and 0.75mg) of Pramipexole Dihydrochloride Sustained-release Tablets (Pramipexole) from the National Me...view
Beilu Yikang, the R&D Subsidiary of Beilu Pharmaceutical, Was Officially Launched
October 12, 2022"Building a multi-level R&D system and actively creating a second growth curve" is the development strategy of the company, and also one of the key tasks of the company in the next few y...view

Gadobutrol Injection Proposed for Selection in the 11th National Drug Centralized Procurement

Jiuwei Zhenxin Granules - Independent Innovation, Classic Inheritance

Introduction of Intravenous Contrast Media

CPHI WORLDWIDE 2023

Foreign Journalists Visit Beilu Pharmaceutical to Learn about Beijing's Green Development

Beilu Pharmaceutical Obtains Drug Registration Certificate for Pramoxine Hydrochloride Sustained Release Tablets

Beilu Yikang, the R&D Subsidiary of Beilu Pharmaceutical, Was Officially Launched